Arecor Therapeutics plc

DB:6UI Stock Report

Market Cap: €34.6m

Arecor Therapeutics Valuation

Is 6UI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6UI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 6UI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6UI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6UI?

Key metric: As 6UI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6UI. This is calculated by dividing 6UI's market cap by their current revenue.
What is 6UI's PS Ratio?
PS Ratio5.9x
SalesUK£4.90m
Market CapUK£28.88m

Price to Sales Ratio vs Peers

How does 6UI's PS Ratio compare to its peers?

The above table shows the PS ratio for 6UI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.1x
2INV 2invest
7.7xn/a€59.8m
HPHA Heidelberg Pharma
12.5x16.6%€106.3m
MDG1 Medigene
3.3x16.1%€24.3m
CNW co.don
0.7xn/a€6.5m
6UI Arecor Therapeutics
5.9x35.2%€28.9m

Price-To-Sales vs Peers: 6UI is good value based on its Price-To-Sales Ratio (5.9x) compared to the peer average (7.8x).

Price to Sales Ratio vs Industry

How does 6UI's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
6UI 5.9xIndustry Avg. 7.7xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6UI is good value based on its Price-To-Sales Ratio (5.9x) compared to the European Biotechs industry average (7.8x).

Price to Sales Ratio vs Fair Ratio

What is 6UI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6UI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.9x
Fair PS Ratio3.8x

Price-To-Sales vs Fair Ratio: 6UI is expensive based on its Price-To-Sales Ratio (5.9x) compared to the estimated Fair Price-To-Sales Ratio (3.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6UI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.89
€4.37
+393.3%
10.1%€4.92€3.84n/a3
Nov ’25€0.87
€4.38
+404.0%
10.6%€4.98€3.84n/a3
Oct ’25€0.73
€4.38
+496.6%
10.6%€4.98€3.84n/a3
Sep ’25€0.97
€4.04
+316.3%
7.4%€4.34€3.74n/a2
Aug ’25€1.05
€4.93
+369.5%
23.4%€6.08€3.78n/a2
Jul ’25€1.33
€5.90
+343.3%
14.9%€6.88€4.75n/a3
Jun ’25€1.79
€5.89
+229.2%
14.9%€6.83€4.72n/a3
May ’25€1.53
€5.52
+260.5%
14.4%€6.31€4.72n/a2
Apr ’25€1.55
€5.52
+255.8%
14.4%€6.31€4.72n/a2
Mar ’25€1.55
€5.48
+253.3%
14.4%€6.27€4.69n/a2
Feb ’25€1.90
€5.48
+188.2%
14.4%€6.27€4.69n/a2
Jan ’25€2.06
€5.23
+154.0%
17.7%€6.16€4.31n/a2
Dec ’24€2.12
€5.23
+146.8%
17.7%€6.16€4.31n/a2
Nov ’24€2.12
€5.16
+143.2%
17.1%€6.04€4.27€0.872
Oct ’24€2.18
€5.16
+136.6%
17.1%€6.04€4.27€0.732
Sep ’24€2.14
€5.16
+141.0%
17.1%€6.04€4.27€0.972
Aug ’24€2.20
€5.16
+134.4%
17.1%€6.04€4.27€1.052
Jul ’24€2.58
€5.16
+99.9%
17.1%€6.04€4.27€1.332
Jun ’24€2.88
€5.16
+79.1%
17.1%€6.04€4.27€1.792
May ’24€2.96
€5.09
+71.9%
15.9%€5.90€4.28€1.532
Apr ’24€2.84
€4.93
+73.7%
18.5%€5.84€4.02€1.552
Mar ’24€2.72
€4.93
+81.3%
18.5%€5.84€4.02€1.552

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$81.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$713.60

7D

-8.3%

1Y

-2.5%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.60

7D

-2.6%

1Y

86.3%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.35

7D

-4.5%

1Y

-2.3%